OptimizeRx (OPRX) Competitors $5.15 -0.07 (-1.34%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends OPRX vs. RMNI, WTRH, LLNW, MXCT, BWMN, OOMA, IBEX, BTOC, SHAP, and EGHTShould you be buying OptimizeRx stock or one of its competitors? The main competitors of OptimizeRx include Rimini Street (RMNI), ASAP (WTRH), Limelight Networks (LLNW), MaxCyte (MXCT), Bowman Consulting Group (BWMN), Ooma (OOMA), IBEX (IBEX), Armlogi (BTOC), Spree Acquisition Corp. 1 (SHAP), and 8X8 (EGHT). OptimizeRx vs. Rimini Street ASAP Limelight Networks MaxCyte Bowman Consulting Group Ooma IBEX Armlogi Spree Acquisition Corp. 1 8X8 Rimini Street (NASDAQ:RMNI) and OptimizeRx (NASDAQ:OPRX) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, community ranking, dividends, earnings, institutional ownership and analyst recommendations. Which has preferable earnings and valuation, RMNI or OPRX? Rimini Street has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Rimini Street, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRimini Street$431.50M0.39$26.06M-$0.37-5.00OptimizeRx$83.20M1.13-$17.57M-$1.00-5.15 Do analysts prefer RMNI or OPRX? Rimini Street presently has a consensus price target of $4.50, suggesting a potential upside of 143.24%. OptimizeRx has a consensus price target of $14.50, suggesting a potential upside of 181.55%. Given OptimizeRx's stronger consensus rating and higher possible upside, analysts plainly believe OptimizeRx is more favorable than Rimini Street.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rimini Street 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00OptimizeRx 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is RMNI or OPRX more profitable? Rimini Street has a net margin of -7.87% compared to OptimizeRx's net margin of -21.53%. OptimizeRx's return on equity of -5.97% beat Rimini Street's return on equity.Company Net Margins Return on Equity Return on Assets Rimini Street-7.87% -83.26% 10.79% OptimizeRx -21.53%-5.97%-4.42% Does the MarketBeat Community favor RMNI or OPRX? Rimini Street received 6 more outperform votes than OptimizeRx when rated by MarketBeat users. However, 63.36% of users gave OptimizeRx an outperform vote while only 63.22% of users gave Rimini Street an outperform vote. CompanyUnderperformOutperformRimini StreetOutperform Votes15363.22% Underperform Votes8936.78% OptimizeRxOutperform Votes14763.36% Underperform Votes8536.64% Does the media refer more to RMNI or OPRX? In the previous week, Rimini Street had 8 more articles in the media than OptimizeRx. MarketBeat recorded 10 mentions for Rimini Street and 2 mentions for OptimizeRx. OptimizeRx's average media sentiment score of 0.77 beat Rimini Street's score of 0.32 indicating that OptimizeRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rimini Street 0 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral OptimizeRx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, RMNI or OPRX? Rimini Street has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Do insiders & institutionals believe in RMNI or OPRX? 73.8% of Rimini Street shares are held by institutional investors. Comparatively, 76.5% of OptimizeRx shares are held by institutional investors. 41.0% of Rimini Street shares are held by company insiders. Comparatively, 6.1% of OptimizeRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryRimini Street beats OptimizeRx on 10 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get OptimizeRx News Delivered to You Automatically Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPRX vs. The Competition Export to ExcelMetricOptimizeRxBusiness services IndustryComputer SectorNASDAQ ExchangeMarket Cap$94.36M$20.04B$23.97B$8.53BDividend YieldN/A2.58%2.75%4.14%P/E Ratio-5.1519.72252.7915.18Price / Sales1.136.103,725.0492.77Price / CashN/A29.8832.0734.07Price / Book0.745.146.985.02Net Income-$17.57M$479.90M$670.43M$225.46M7 Day Performance-5.68%-0.91%-0.32%0.37%1 Month Performance-32.15%-3.40%0.65%3.57%1 Year Performance-38.03%28.62%20.34%29.44% OptimizeRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPRXOptimizeRx2.5855 of 5 stars$5.15-1.3%$14.50+181.6%-36.4%$94.36M$83.20M-5.15100News CoverageRMNIRimini Street3.5252 of 5 stars$1.77+11.3%$4.50+154.2%-22.9%$144.21M$431.50M-4.782,120Earnings ReportNews CoverageHigh Trading VolumeWTRHASAPN/AN/AN/AN/A$19.35M$130.00M-0.091,034LLNWLimelight Networks0.4711 of 5 starsN/AN/AN/A$339.96M$217.63M-6.31556MXCTMaxCyte2.9021 of 5 stars$3.58+1.1%$8.67+142.1%+14.9%$372.30M$41.29M-10.53143Upcoming EarningsNews CoverageBWMNBowman Consulting Group3.6262 of 5 stars$20.30-3.5%$40.10+97.5%-20.4%$369.56M$386.81M-27.072,000Upcoming EarningsShort Interest ↓News CoverageOOMAOoma1.4001 of 5 stars$11.96-3.8%$14.50+21.2%+15.4%$333.12M$236.74M-62.951,221IBEXIBEX2.846 of 5 stars$17.96-2.0%$20.50+14.1%+8.7%$307.14M$508.57M9.7130,000Upcoming EarningsBTOCArmlogiN/A$6.87+15.3%N/AN/A$285.79M$166.98M0.00N/AHigh Trading VolumeSHAPSpree Acquisition Corp. 1N/A$10.91flatN/AN/A$283.07MN/A0.00N/AEGHT8X82.5317 of 5 stars$2.23+2.8%$2.93+31.3%-3.9%$278.48M$728.71M-4.461,948Upcoming Earnings Related Companies and Tools Related Companies Rimini Street Alternatives ASAP Alternatives Limelight Networks Alternatives MaxCyte Alternatives Bowman Consulting Group Alternatives Ooma Alternatives IBEX Alternatives Armlogi Alternatives Spree Acquisition Corp. 1 Alternatives 8X8 Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OPRX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.